Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

March 17, 2021

Study Completion Date

April 7, 2021

Conditions

Healthy

Interventions

DRUG

test apixaban tablets

specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China

DRUG

reference apixaban tablets

specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA

Trial Locations (1)

The Affiliated Hospital of Qingdao University Phase I Clinical Research Center, Qingdao

All Listed Sponsors

lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05841446 - Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter